(Q31044439)

English

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 June 2017

0 references

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data (English)

1 reference

Europe PubMed Central

28 June 2017

1 reference

based on heuristic

inferred from title

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

David Preiss

2

0 references

1

object named as

Naveed Sattar

1 reference

Europe PubMed Central

28 June 2017

Frederick J Raal

8

object named as

Frederick J Raal

1 reference

Europe PubMed Central

28 June 2017

author name string

Jennifer G Robinson

3

1 reference

Europe PubMed Central

28 June 2017

C Stephen Djedjos

4

1 reference

Europe PubMed Central

28 June 2017

Mary Elliott

5

1 reference

Europe PubMed Central

28 June 2017

Ransi Somaratne

6

1 reference

Europe PubMed Central

28 June 2017

Scott M Wasserman

7

1 reference

Europe PubMed Central

28 June 2017

publication date

8 February 2016

1 reference

Europe PubMed Central

28 June 2017

The Lancet: Diabetes & Endocrinology

1 reference

Europe PubMed Central

28 June 2017

4

1 reference

Europe PubMed Central

28 June 2017

5

1 reference

Europe PubMed Central

28 June 2017

403-410

1 reference

Europe PubMed Central

28 June 2017

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900003-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900003-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900003-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Diabetes mellitus, fasting glucose, and risk of cause-specific death

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900003-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Major lipids, apolipoproteins, and risk of vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900003-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Lipids and lipoproteins in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900003-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The PCSK9 decade

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900003-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900003-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900003-6

7 January 2021

based on heuristic

inferred from DOI database lookup

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900003-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900003-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of Cardiometabolic Multimorbidity With Mortality

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900003-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900003-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900003-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic variants associated with Lp(a) lipoprotein level and coronary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900003-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900003-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900003-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Does pharmacologic treatment in patients with established coronary artery disease and diabetes fulfil guideline recommended targets? A report from the EUROASPIRE III cross-sectional study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900003-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900003-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900003-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900003-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900003-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900003-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900003-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-8587(16)00003-6

1 reference

Europe PubMed Central

28 June 2017

1 reference

Europe PubMed Central

28 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31044439&oldid=1830292262"